With revenue up 9%, why does the NIB share price keep falling?

Will the ailing share price make a full recovery?

| More on:
Stethoscope with a piggy bank in the middle.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The NIB Holdings Limited (ASX: NHF) share price has suffered a very unhealthy decline of 27% in the past 12 months. That's despite the S&P/ASX 200 Index (ASX: XJO) rising roughly 12%, meaning the ASX healthcare share has underperformed by close to a whopping 40%.

Created with Highcharts 11.4.3NIB Holdings PriceZoom1M3M6MYTD1Y5Y10YALL12 Feb 202412 Feb 2025Zoom ▾Mar '24May '24Jul '24Sep '24Nov '24Jan '25Apr '24Apr '24Jul '24Jul '24Oct '24Oct '24Jan '25Jan '25www.fool.com.au

The decline has also happened despite NIB still growing in scale during this period, so it begs the question of what's going on and whether this is an opportunity. It grew its revenue by 9% in FY24.

It's normal for there to be difficulties for specific industries sometimes. Private health insurance is a niche industry compared to general insurance, in my view, with more complexity due to private hospitals and government funding involvement.

What's going on in the private health industry?

Operators like NIB and Medibank Private Ltd (ASX: MPL) are partly dependent on the overall health of the private system.

Investment bank Goldman Sachs thinks industry policyholder growth has remained "resilient" through the first half of FY25 ("perhaps surprising to the upside", in the broker's words), though it notes weakening affordability for Australians. This may be a key driver of the NIB share price, in my view.

Goldman Sachs also suggested that the "competitive environment for policyholder acquisition is still strong resulting in lapses / churn reverting toward pre-COVID levels".

Policyholder growth has been supported by factors like population growth, first-time take-ups of private health insurance, and younger age groups, according to Goldman Sachs.

The industry has been under pressure to keep a lid on premium increases to help affordability and reduce inflation. However, Goldman Sachs believes the April 2025 approved premium rate increases could be higher than 2024 because of "hospital indexation/inflation (including nurse wages) as well as higher bed rates for private patients in NSW public hospitals."

The broker is concerned that the risks for the profit margins of NIB (and Medibank) "are building with inflationary pressures and low approved premium rate increases". NIB is expecting to achieve net margins within its target net margin range of between 6% and 7%.

Is the NIB share price attractive?

The group underlying operating profit (UOP) guidance from NIB is $235 million to $250 million, with Goldman Sachs thinking NIB will be at the bottom end of that range.

Overall, for the FY25 first-half result, the broker expects NIB to achieve insurance revenue of $1.71 billion, an insurance operating profit of $93.6 million, and an underlying operating profit of $101.4 million. The forecast FY25 half-year dividend is 11.1 cents per share.

For the full FY25 result, Goldman Sachs projects $3.7 billion of revenue, $216.7 million of insurance operating profit, and $236.5 million of underlying operating profit, with a possible annual dividend per share of 26.5 cents.

At the current NIB share price, it's valued at 15x FY25's estimated earnings with a possible grossed-up dividend yield, including franking credits.

If investors are interested in NIB shares, then I'd say this is the right time to look at the company. Goldman Sachs currently has a buy rating on NIB shares with a price target of $6.50, implying a possible 12-month rise of just over 10% from where it is today.

Should you invest $1,000 in Nib Holdings right now?

Before you buy Nib Holdings shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Nib Holdings wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 6 March 2025

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group. The Motley Fool Australia has positions in and has recommended NIB Holdings. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should you buy the dip on the CSL share price?

Has the market sell-off created an opportunity to buy this mega ASX 200 blue chip at an attractive price?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 136% in a year, why is this ASX 200 share slipping on Wednesday?

The high-performing ASX 200 share is expanding its product pipeline.

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Healthcare Shares

Meet the dirt cheap ASX 200 stock that could rocket 75%

Bell Potter thinks investors should be snapping up this stock while it is down in the dumps.

Read more »

A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.
Healthcare Shares

This ASX 200 healthcare share is sinking 9% on CEO exit

Investors are selling off this stock on Tuesday. Here's what you need to know.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why is the CSL share price falling on Monday?

The ASX 200 biotech stock has lost 9% of its value since the start of the new year.

Read more »

Health professional working on his laptop.
Healthcare Shares

Are Sonic Healthcare or CSL shares a better buy?

Which of these healthcare giants is a better buy?

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Dividend Investing

Hoping to bag the boosted dividend from CSL shares? Here's your deadline…

The ASX 200 biotech is rewarding investors with a 9% higher interim dividend this year.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

2 ASX healthcare shares rated as top buys

Are these two names healthy choices for your portfolio? Let's see.

Read more »